Canada Life’s CytomX Therapeutics CTMX Stock Holding History

Canada Life’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,623	Closed	-$13K	–	2518
2021 Q3	$13K	Hold	2,623	–	–	﹤0.01%	2486
2021 Q2	$17K	Hold	2,623	–	–	﹤0.01%	2507
2021 Q1	$20K	Hold	2,623	–	–	﹤0.01%	2505
2020 Q4	$17K	Hold	2,623	–	–	﹤0.01%	2560
2020 Q3	$17K	Hold	2,623	–	–	﹤0.01%	2469
2020 Q2	$22K	Hold	2,623	–	–	﹤0.01%	2476
2020 Q1	$20K	Hold	2,623	–	–	﹤0.01%	2371
2019 Q4	$22K	Buy	+2,623	New	+$17.7K	﹤0.01%	2476
2019 Q3	–	Sell	-4,943	Closed	-$55K	–	1393
2019 Q2	$55K	Hold	4,943	–	–	﹤0.01%	2414
2019 Q1	$53K	Hold	4,943	–	–	﹤0.01%	2243
2018 Q4	$72K	Hold	4,943	–	–	﹤0.01%	2251
2018 Q3	$91K	Hold	4,943	–	–	﹤0.01%	2222
2018 Q2	$113K	Buy	4,943 +3,143	+175%	+$80.3K	﹤0.01%	2147
2018 Q1	$51K	Hold	1,800	–	–	﹤0.01%	2362
2017 Q4	$38K	Hold	1,800	–	–	﹤0.01%	2421
2017 Q3	$32K	Hold	1,800	–	–	﹤0.01%	2424
2017 Q2	$28K	Hold	1,800	–	–	﹤0.01%	2450
2017 Q1	$31K	Hold	1,800	–	–	﹤0.01%	2401
2016 Q4	$20K	Hold	1,800	–	–	﹤0.01%	2491
2016 Q3	$28K	Hold	1,800	–	–	﹤0.01%	2435
2016 Q2	$18K	Buy	+1,800	New	+$20.5K	﹤0.01%	2473

Other funds holding CTMX

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Canada Life's CTMX Position: Q4 2021 in Review

Canada Life sold out of CytomX Therapeutics (CTMX) in Q4 2021, closing a stake of 2,623 shares — an estimated $13K sold.

Canada Life first reported a position in CTMX in Q2 2016 and held it in 21 quarters. The position peaked at $113K in Q2 2018. 110 funds tracked by Wall St. Rank hold CTMX as of Q4 2021.

Canada Life reported no remaining CytomX Therapeutics position as of Q4 2021 after selling out during the quarter.
Canada Life sold 2,623 CytomX Therapeutics shares in Q4 2021, an estimated $13K.
Canada Life first reported a position in CytomX Therapeutics in Q2 2016 and held it in 21 quarters.
Canada Life's CytomX Therapeutics position peaked at $113K in Q2 2018.
110 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2021.

Based on Canada Life's 13F filing for Q4 2021, filed 14 Feb 2022.